Poseida Sinks On Prostate Cancer CAR-T Clinical Hold
The Newly Public Company’s Stock Closed Down 30%
Poseida’s technologies are designed to deliver safer, more effective cell and gene therapies, but the first trial for its autologous PSMA-targeting CAR-T therapy was put on a clinical hold after a patient died.
